Global Immunotherapy Drugs Market worth 73,529.2 Million USD by 2020

Browse 37 market data tables and 29 figures spread through 126 pages and in-depth TOC on "Immunotherapy Drugs Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, (Therapeutic Vaccines and Preventive Vaccines), Checkpoint Inhibitors), Epidemiology, Regulatory and Pipeline Analysis - Global Forecast to 2020"
Early buyers will receive 10% customization on reports.

Download PDF Brochure@

The Immunotherapy Drugs market is poised to reach USD 73,529.2 Million by 2020 from USD 40,281.6 Million in 2015, at a CAGR of 12.8% from 2015 to 2020.

Factors such as changing demographics increase in disease incidence, rising focus on therapies with fewer side effects, and acceleration of review and approval processes are driving the growth of the immunotherapy drugs market. However, factors such as the high cost of immunotherapy treatments and limited accessibility of immunotherapy drugs among low- and middle-income patients are restraining the growth of this market.

Speak To Analyst@

The immunotherapy drugs market, by type, comprises five categories monoclonal antibodies, interferons, interleukins, vaccines, and checkpoint inhibitors. The vaccines segment is further divided into therapeutic and preventive vaccines. The monoclonal antibodies segment is expected to account for the largest share of the immunotherapy drugs products market in 2015, as there are many approved drugs for cancer treatment. However, the checkpoint inhibitors segment is one of the newer segments in the immunotherapy sector and estimated to witness the highest growth rate in the immunotherapy drugs market.

Major players operating in the Immunotherapy Drugs market are as Amgen Inc. (U.S.), GlaxoSmithKline Plc. (U.K.), Merck & Co., Inc. (U.S.), Novartis International Ag (Switzerland),and Roche Holding Ag (Switzerland).

About MarketsandMarkets

MarketsandMarkets is world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.

M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Mr. Rohan
Markets and Markets
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India